- NEWS
- Correction 03 June 2020
- Correction 03 June 2020
Investors keep the faith in cancer liquid biopsies
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Biotechnology 37, 972-974 (2019)
doi: https://doi.org/10.1038/d41587-019-00022-7
Updates & Corrections
-
Correction 03 June 2020: An earlier version of this article omitted mention in Table 1 of Guardant360’s FDA breakthrough device designation 15 February 2018
-
Correction 03 June 2020: The Table 1 incorrectly stated that MirXes’ products were at research stage when GastroClear has been available in Singapore since its approval on 9 May 2019 by the Singapore by the Health Sciences Authority.